• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Rapid Micro Biosystems, Inc.

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact
rapidmicro

Rapid Micro Biosystems, Inc.

Investment: 2009; IPO 2021
Visit Website

Rapid Micro Biosystems creates innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products.

The company’s Growth Direct™—the first and only growth-based system to automate compendial testing—detects contamination more quickly, delivering compelling economic benefits to manufacturers while improving their quality control (QC) process.

Growth Direct addresses all key microbial QC applications and fits with current regulatory practices, a critical accelerator for adoption. Automated, accelerated analysis eliminates error-prone manual steps and saves labor. Rapid detection of contamination enables manufacturers to reduce inventory carrying costs, shorten manufacturing cycles, and reduce product losses, delivering significant cost savings and increased operational efficiency.

Rapid Micro Biosystems’ proprietary technology is based on the detection of natural autofluorescence. The inventors of the core principle, “efficient blue light-emitting diodes, which has enabled bright and energy-saving white light sources,” won the Nobel Prize in Physics.

Rapid Micro Biosystems is headquartered in Lowell, Massachusetts, with operations in Lowell and Freising, Germany.

 

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact